The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

BACKGROUND: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hongjuan, Ning, Shoucheng, Nolley, Rosalie, Scicinski, Jan, Oronsky, Bryan, Knox, Susan J., Peehl, Donna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270305/
https://www.ncbi.nlm.nih.gov/pubmed/28149332
http://dx.doi.org/10.1186/s13148-017-0312-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270305/
https://www.ncbi.nlm.nih.gov/pubmed/28149332
http://dx.doi.org/10.1186/s13148-017-0312-z

Ejemplares similares